Newsroom

Newsroom - 2024

Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24

Glenmark partners with Pfizer to launch Abrocitinib in India

Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance ‐ ‘Ichnos Glenmark Innovation’

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India